RE: Rns26 Jun 2025 11:46
The research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.
some chunky trades in the coming weeks would and fuel to the fire.
Dr. Karl Keegan's Biography
Karl has worked in the Life Sciences sector for over 25 years and has covered a number of impressive stocks and transactions during his career, including the $1 billion IPO of Serono on the New York Stock Exchange as well as the IPO of Genmab (which was the largest IPO in Europe at the time). In addition to this, Karl has a PhD in combined scientific training with finance (MSc) and has been a top rated analyst in the UK, US and Canada.